KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Receivables - Other: 2017-2023

Historic Receivables - Other for BeOne Medicines (ONC) over the last 6 years, with Dec 2023 value amounting to $1.7 million.

  • BeOne Medicines' Receivables - Other fell 42.91% to $1.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.7 million, marking a year-over-year decrease of 42.91%. This contributed to the annual value of $1.7 million for FY2023, which is 42.91% down from last year.
  • As of Q4 2023, BeOne Medicines' Receivables - Other stood at $1.7 million, which was up 6.57% from $1.6 million recorded in Q3 2023.
  • BeOne Medicines' Receivables - Other's 5-year high stood at $12.7 million during Q4 2020, with a 5-year trough of $1.3 million in Q1 2023.
  • In the last 3 years, BeOne Medicines' Receivables - Other had a median value of $2.8 million in 2022 and averaged $3.8 million.
  • In the last 5 years, BeOne Medicines' Receivables - Other crashed by 77.57% in 2019 and then surged by 554.81% in 2020.
  • Over the past 5 years, BeOne Medicines' Receivables - Other (Quarterly) stood at $1.9 million in 2019, then spiked by 554.81% to $12.7 million in 2020, then slumped by 60.07% to $5.1 million in 2021, then crashed by 39.85% to $3.0 million in 2022, then plummeted by 42.91% to $1.7 million in 2023.
  • Its Receivables - Other stands at $1.7 million for Q4 2023, versus $1.6 million for Q3 2023 and $2.0 million for Q2 2023.